Annals for Hospitalists Inpatient Notes - Novel and Advanced Therapies for Heart Failure—What a Hospitalist Needs to Know
Authors: Supriya Shore, Brahmajee Nallamothu
Journal: Annals of Internal Medicine (2020)

Web Exclusives15 September 2020Annals for Hospitalists Inpatient Notes - Novel and Advanced Therapies for Heart Failure—What a Hospitalist Needs to KnowSupriya Shore, MD, MSCS and Brahmajee Nallamothu, MD, MPHSupriya Shore, MD, MSCSUniversity of Michigan, Ann Arbor, Michigan (S.S., B.N.)Search for more papers by this author and Brahmajee Nallamothu, MD, MPHUniversity of Michigan, Ann Arbor, Michigan (S.S., B.N.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-5721 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Heart failure (HF) is one of the most common causes of hospitalization and has significant financial implications in the current era because of statutory penalties for rehospitalizations imposed with the Patient Protection and Affordable Care Act. Contemporary data suggest that although HF hospitalization rates have declined, mortality among those hospitalized remains high, approaching a rate of greater than 20% in the first month after discharge. This highlights an important opportunity for improvement because attempts to reduce rehospitalization risk have not translated into lower mortality risk. Hospitalists care for a large majority of hospitalized patients with HF and can play a ...References1. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. [PMID: 25176015] doi:10.1056/NEJMoa1409077 CrossrefMedlineGoogle Scholar2. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. [PMID: 31535829] doi:10.1056/NEJMoa1911303 CrossrefMedlineGoogle Scholar3. Swedberg K, Komajda M, Böhm M, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875-85. [PMID: 20801500] doi:10.1016/S0140-6736(10)61198-1 CrossrefMedlineGoogle Scholar4. Armstrong PW, Pieske B, Anstrom KJ, et al; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883-1893. [PMID: 32222134] doi:10.1056/NEJMoa1915928 CrossrefMedlineGoogle Scholar5. Rogers JG, Patel CB, Mentz RJ, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017;70:331-341. [PMID: 28705314] doi:10.1016/j.jacc.2017.05.030 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Michigan, Ann Arbor, Michigan (S.S., B.N.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-5721.Corresponding Author: Supriya Shore, MD, MSCS, University of Michigan, NCRC 16-169C, 2800 Plymouth Road, SPC 2800, Ann Arbor, MI 48109-2800; e-mail, [email protected]umich.edu.Current Author Addresses: Dr. Shore: University of Michigan, NCRC 16-169C, 2800 Plymouth Road, SPC 2800, Ann Arbor, MI 48109-2800.Dr. Nallamothu: University of Michigan, NCRC 16, 2800 Plymouth Road, SPC 2800, Ann Arbor, MI 48109-2800. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAnnals for Hospitalists - 15 September 2020 David H. Wesorick and Vineet Chopra Metrics 15 September 2020Volume 173, Issue 6Page: HO2-HO3 ePublished: 15 September 2020 Issue Published: 15 September 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...